Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...

Pfizer Inc. has just upgraded its 2025 earnings forecast, fueling a bullish sentiment among analysts. After its Q2 earnings ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

The Food and Drug Administration (FDA) may not re-authorize Pfizer's COVID vaccine for children under the age of 5, the ...

Pfizer, Inc. (PFE) stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance.

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

In search of a better approach to designing and developing these small proteins, researchers turned to ProtGPT2.

The FDA cautions the outcomes described in the complaints may have no connection to the drugs or could be unexpected side effects.

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...